AB 2302 requires manufacturers who sell or distribute infant formula in California to test representative samples of each production aggregate for five named toxic elements and to make test results available to consumers. The bill also sets minimum standards for the laboratories that perform the testing and requires labeled machine-readable links to the results when federal action levels exist.
The measure aims to increase transparency about trace toxic elements in infant formula by combining routine testing, public disclosure on manufacturer websites (in English and Spanish), and a label-based QR code linking consumers to test data and FDA guidance. Companies will need to adapt sampling, testing, recordkeeping, and labeling practices to comply.
At a Glance
What It Does
Requires manufacturers of infant formula sold in California to test representative samples of each production aggregate for aluminum, arsenic, cadmium, lead, and mercury, and to post the results on their websites for the product shelf life plus one month. It also requires laboratories to meet ISO/IEC 17025:2017 accreditation and specified analytical and proficiency standards.
Who It Affects
Applies to any manufacturer whose final infant formula product is sold, manufactured, delivered, held, or offered for sale in California. It affects product development, manufacturing quality teams, regulatory and labeling functions, and third-party testing laboratories.
Why It Matters
This bill creates a state-specific testing and disclosure regime that supplements federal oversight by obligating routine, batch-level reporting and setting lab proficiency standards, which will change compliance budgets and supply-chain verification for formula makers and expand consumer-facing product information.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2302 defines which products and actors fall under its scope and then imposes three linked requirements: test, disclose, and use accredited labs. The bill treats a "final infant formula product" as the finished item identified by a UPC and requires manufacturers to test representative samples from each production aggregate for five toxic elements (aluminum, arsenic, cadmium, lead, mercury).
Manufacturers may take those samples and run tests before packaging individual units, but the requirement is keyed to production aggregates, not single retail units.
On disclosure, the bill forces manufacturers to post, on their public websites and in both English and Spanish, the name and measured level of each toxic element for each production aggregate for the duration of the product's shelf life plus one month. The manufacturer must also provide descriptive identifiers (for example, UPC, size, lot or batch numbers) so consumers can match data to a purchased product.
If the FDA has an action level, regulatory limit, or tolerance for a given element, the bill requires the product label to carry a QR or similar machine-readable code that links directly to the manufacturer's test results page and to FDA resources, plus a short instruction to scan the code for testing information.Testing must be done at a "proficient laboratory," which the bill defines by three criteria: ISO/IEC 17025:2017 accreditation; use of analytical methods at least as sensitive as those in the FDA Elemental Analysis Manual 4.7; and demonstrated proficiency in independently quantifying each toxic element down to at least 6 μg/kg with a z-score of ≤ ±2 in proficiency testing. Manufacturers must run representative-sample testing at least once per month for each final product and produce results to authorized state agents on request.
Taken together, the requirements create recurring operational work: sampling plans, contract lab agreements that meet the stated standards, website and label updates, and processes to deliver test records to regulators.
The Five Things You Need to Know
The bill defines "toxic elements" as aluminum, arsenic, cadmium, lead, and mercury and requires testing for each of these elements.
Manufacturers must test a representative sample of each production aggregate at least once per month; testing may occur before individual unit packaging.
Manufacturers must post test results on their websites in English and Spanish for the product shelf life plus one month, including product identifiers such as UPC or lot numbers.
If the FDA has an action level for a tested element, the product label must include a QR code linking to the manufacturer's test results page and an FDA information link, plus a short scan instruction.
The laboratory must be ISO/IEC 17025:2017 accredited, use methods at least as sensitive as FDA Elemental Analysis Manual 4.7, and demonstrate proficiency to quantify each element to at least 6 μg/kg with a proficiency z-score ≤ ±2.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions that set the scope
Subdivision (a) establishes the operative vocabulary: what counts as a final infant formula product (finished product identified by UPC), what toxic elements are covered, the meaning of product shelf life, production aggregate, proficient laboratory, representative sample, and QR code. Those definitions control both the unit of testing and the public-disclosure unit. Practically, a manufacturer and its counsel will use these definitions to design sampling plans, determine which SKUs fall under the rule, and decide whether existing lot-coding and labeling practices already satisfy the bill's identification and website-disclosure expectations.
Testing obligation and access to results
This subsection obligates manufacturers to test representative samples from each production aggregate for the five named toxic elements and to do so at least monthly. The language allows testing prior to individual packaging, which gives manufacturers flexibility to integrate testing into bulk quality control operations. The requirement to provide test results to an "authorized agent" of the department on request creates an enforcement pathway: companies should maintain accessible records, traceable to the production aggregate identifiers posted publicly, to respond to regulator inquiries quickly.
Public disclosure and labeling tied to FDA action levels
Manufacturers must keep an easily accessible web page—available in English and Spanish—showing the name and level of each toxic element for each production aggregate and identifying information to let consumers match results to purchased products. The bill conditions a label-based QR-code requirement on the existence of an FDA action level: when such a federal limit exists for an element, the label must carry a machine-readable code linking both to the manufacturer's results page and to FDA guidance, plus a short instruction to scan. That design ties state disclosure to federal regulatory benchmarks while still requiring disclosure even where the FDA has not set specific tolerances.
Laboratory standards and proficiency requirements
The bill requires testing laboratories to be ISO/IEC 17025:2017 accredited, to use analytical methods at least as sensitive as those in the FDA's Elemental Analysis Manual 4.7, and to demonstrate independent proficiency in quantifying each toxic element to at least 6 μg/kg with a z-score ≤ ±2. For manufacturers this means vetting and likely qualifying new lab partners, and for labs it creates concrete entry requirements for servicing California-bound formula. The proficiency standard focuses on inter-lab comparability and sensitivity but will pressure labs to participate in appropriate proficiency-testing schemes that include the specified elements at the stated detection levels.
Disclosure to department agents and practical compliance steps
The bill authorizes department agents to request test results under existing state inspection authorities cited in the text. Compliance will therefore depend on record retention, rapid retrieval of production-aggregate test data, and coordination between manufacturing, quality-control, and legal/regulatory teams. Operationally, manufacturers should expect to formalize sampling protocols, log lot-to-UPC mappings, maintain web pages with authenticated test files, and ensure labels carry the required machine-readable codes where federal action levels apply.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Parents and caregivers in California — they gain direct access to batch-level measurements of five toxic elements, enabling more informed purchasing decisions for infants vulnerable to toxic exposures.
- Public health agencies and researchers — standardized, accessible test data can improve surveillance of contaminant levels across brands and time, informing risk assessments and potential regulatory action.
- Pediatric healthcare providers — clinicians gain a transparent data source to better advise families when questions about trace elements in formula arise.
Who Bears the Cost
- Infant formula manufacturers — they must establish routine monthly sampling, secure ISO/IEC 17025:2017-accredited labs that meet method sensitivity and proficiency criteria, update websites and potentially labels, and maintain records for regulator review.
- Testing laboratories — accredited labs may face increased demand to meet the specific analytical sensitivity and proficiency thresholds, requiring investment in methods, QA programs, and participation in proficiency testing.
- Smaller or specialty formula producers and private-label manufacturers — these firms may face proportionally higher per-unit compliance costs and administrative burdens compared with larger manufacturers with established QC and lab networks.
Key Issues
The Core Tension
The bill pits the public interest in transparency and routine monitoring of toxic elements in infant formula against operational and interpretive costs: ensuring frequent, production-level testing and public disclosure could improve safety oversight but also raises compliance burdens, supply-chain strain, and the risk that consumers will misread low-level, non-actionable detections absent federal benchmarks.
AB 2302 leaves several implementation and interpretation questions unresolved. The bill mandates "representative samples" but does not specify sampling protocols (sample size formulas, statistical confidence levels, or how to treat multi-site production), which means manufacturers and regulators will have to negotiate acceptable sampling plans or await implementing guidance.
The monthly testing cadence could under- or over-sample relative to production rhythm: for high-volume continuous lines monthly testing may miss within-month variability, while for low-volume or seasonal products monthly testing could impose an outsized cost per tested unit.
The bill also creates potential friction with federal regulatory architecture. While it ties label QR-code obligations to existing FDA action levels, it requires testing for elements irrespective of FDA tolerances; consequently, manufacturers may disclose trace-level findings that the FDA considers acceptable or background.
That raises a consumer-communication problem: raw numbers without context or uniform interpretive benchmarks risk being misunderstood and could trigger consumer alarm or litigation. Finally, the lab proficiency and sensitivity requirements are precise but depend on availability of proficiency-test materials and accredited labs able to demonstrate the stated z-score performance at 6 μg/kg.
If lab capacity is limited, manufacturers could face delays, higher costs, or the need to invest in on-site capabilities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.